中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.019 seconds)

    Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
    2.
    发明申请
    Parenteral formulations of peptides for the treatment of systemic lupus erythematosus 审中-公开
    用于治疗系统性红斑狼疮的肽的肠胃外制剂

    公开(公告)号：US20090169559A1

    公开(公告)日：2009-07-02

    申请号：US12291439

    申请日：2008-11-10

    Applicant: Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    Inventor： Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    IPC: A61K39/395

    CPC classification number: C07K7/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/1709 ,  C07K7/08 ,  C07K14/4713 ,  C07K2319/00

    Abstract: The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two of the sequences in (a)(i), (a)(ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a)(i), (a)(ii) and (b)(i) through (b)(x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.

    Abstract translation: 本发明提供一种药物组合物，其包含：水性载体; 从0.1mg / ml至20mg / ml组合物的药学上可接受的盐a）包含至少12个和至多30个连续氨基酸的肽，其具有对应于（i）在 人单克隆抗-DNA 16/6 Id抗体的重链或轻链的互补决定区（CDR），或（ii）在重链或重链或重链的互补决定区（CDR）内存在的氨基酸序列， 致病性抗DNA单克隆抗体的轻链，其在小鼠中诱导系统性红斑狼疮（SLE）样疾病反应，或b）包含具有SEQ ID NOS中任一个所示序列的连续氨基酸的肽。 （a）（i），（a）（ii）和（b）中的至少两个序列的连续氨基酸的肽包含a）和b）中任一个的序列，或c） （i）至（b）（x）所述的肽，或d）包含连续氨基酸的肽，其具有包含（a）（i），（a）（ii）和（b） ）通过（b）（x）; 和溶解度增强剂，其中肽和溶解度增强剂都溶解在水性载体中; 并且其中所述组合物的pH为4至9，以及通过施用有效量的组合物来减轻人类SLE症状的方法。

    Rasagiline Orally Disintegrating Compositions
    3.
    发明申请
    Rasagiline Orally Disintegrating Compositions 审中-公开
    雷沙吉兰口腔崩解组合物

    公开(公告)号：US20090111892A1

    公开(公告)日：2009-04-30

    申请号：US11791684

    申请日：2005-11-17

    Applicant: Shulamit Patashnik ,  Daniella Licht ,  Adrian Gilbert

    Inventor： Shulamit Patashnik ,  Daniella Licht ,  Adrian Gilbert

    IPC: A61K31/136

    CPC classification number: A61K31/135 ,  A61K31/136

    Abstract: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.

    Abstract translation: 本发明提供了一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰的药学上可接受的盐，以及具有至少两种糖醇的非丝状微结构的颗粒。 本发明还提供一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰的药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒的混合物，补充糖醇，补充流 代理和补充崩解剂。 本发明还提供了治疗患有帕金森病的受试者的方法，其包括向受试者施用治疗有效量的固体药物组合物，从而治疗受试者。 最后，本发明提供制备这种固体药物组合物的方法。

    Multi-network monitoring architecture
    5.
    发明申请
    Multi-network monitoring architecture 审中-公开
    多网络监控架构

    公开(公告)号：US20050235058A1

    公开(公告)日：2005-10-20

    申请号：US10961011

    申请日：2004-10-08

    Applicant: Phil Rackus ,  Claudiu Carter ,  Jean Fauteux ,  Adrian Gilbert

    Inventor： Phil Rackus ,  Claudiu Carter ,  Jean Fauteux ,  Adrian Gilbert

    IPC: H04L12/24 ,  H04L12/26 ,  G06F15/173 ,  G06F11/00

    CPC classification number: H04L41/046 ,  H04L41/0681 ,  H04L43/00 ,  H04L43/0811 ,  H04L43/0817 ,  H04L43/12 ,  H04L43/16

    Abstract: A network monitoring architecture for multiple computer network systems is disclosed. In particular, the network monitoring architecture includes an agent system installed within each computer network and a remote central management unit in communication with the agent system of each computer network. The agent systems collect data from key network devices that reside on the corresponding computer network, and send the collected data to the remote central management unit as a message through the Internet. The data from the computer networks are processed at the remote central management unit to determine imminent or actual failure of the monitored network devices. The appropriate technicians can be immediately notified by the central management unit through automatically generated messages.

    Abstract translation: 公开了一种用于多计算机网络系统的网络监控架构。 特别地，网络监视架构包括安装在每个计算机网络内的代理系统和与每个计算机网络的代理系统通信的远程中央管理单元。 代理系统从驻留在相应计算机网络上的关键网络设备收集数据，并将收集的数据作为消息通过Internet发送到远程中央管理单元。 来自计算机网络的数据在远程中央管理单元处理，以确定被监控网络设备的即将发生或实际故障。 相应的技术人员可以通过自动生成的消息立即通知中央管理单位。

    Orally disintegrating compositions
    8.
    发明申请
    Orally disintegrating compositions 审中-公开
    口腔崩解组合物

    公开(公告)号：US20080107729A1

    公开(公告)日：2008-05-08

    申请号：US11805871

    申请日：2007-05-23

    Applicant: Arun F. Amin ,  Sarath Chandar ,  Adrian Gilbert ,  Dannit Licht ,  Gary T. Norman ,  Shuli Patashnik

    Inventor： Arun F. Amin ,  Sarath Chandar ,  Adrian Gilbert ,  Dannit Licht ,  Gary T. Norman ,  Shuli Patashnik

    IPC: A61K9/20 ,  A61K47/10

    CPC classification number: A61K9/2018 ,  A61K9/0056

    Abstract: This invention provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. Finally, this invention provides a process of making such solid pharmaceutical compositions.

    Abstract translation: 本发明提供一种固体药物组合物，其包含活性成分（例如雷沙吉兰）或其药学上可接受的盐，以及具有至少两种糖醇的非丝状微结构的颗粒。 本发明还提供一种固体药物组合物，其包含活性成分（例如雷沙吉兰）或其药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒的混合物，补充剂 糖醇，补充流剂和补充崩解剂。 最后，本发明提供制备这种固体药物组合物的方法。

Patent Agency Ranking